By Nick Johnson (Apyx) In 2024 Shareholder News, 2025 Shareholder News, J-Plasma, RenuvionPosted January 13, 2025APYX MEDICAL CORPORATION REPORTS PRELIMINARY FOURTH QUARTER AND FULL YEAR 2024 REVENUE RESULTS READ MORE
By Nick Johnson (Apyx) In 2024 Shareholder News, RenuvionPosted January 6, 2025APYX MEDICAL CORPORATION SUBMITS 510(K) PREMARKET NOTIFICATION TO THE U.S. FOOD AND DRUG ADMINISTRATION FOR THE AYON BODY CONTOURING SYSTEM™ READ MORE
By Nick Johnson (Apyx) In 2024 Shareholder News, RenuvionPosted December 2, 2024APYX MEDICAL CORPORATION TO PARTICIPATE IN THE PIPER SANDLER 36TH ANNUAL HEALTHCARE CONFERENCE READ MORE
By Nick Johnson (Apyx) In 2024 Shareholder News, J-Plasma, RenuvionPosted November 8, 2024APYX MEDICAL CORPORATION ANNOUNCES $7,000,000 MILLION REGISTERED DIRECT OFFERING READ MORE
By Nick Johnson (Apyx) In 2024 Shareholder News, J-Plasma, RenuvionPosted November 7, 2024Apyx Medical Corporation Reports Third Quarter 2024 Financial Results; Updates Full Year 2024 Financial Outlook and Introduces Full Year 2025 Financial Outlook READ MORE
By Nick Johnson (Apyx) In 2024 Shareholder News, J-Plasma, RenuvionPosted October 24, 2024APYX MEDICAL CORPORATION TO RELEASE THIRD QUARTER OF FISCAL YEAR 2024 FINANCIAL RESULTS ON NOVEMBER 8, 2024 READ MORE
By Nick Johnson (Apyx) In 2024 Shareholder News, RenuvionPosted August 13, 2024RENUVION NAMED #1 TRUSTED BODY CONTOURING TECHNOLOGY BY DOCTORS* READ MORE
By Nick Johnson (Apyx) In 2024 Shareholder News, J-Plasma, RenuvionPosted August 8, 2024APYX MEDICAL CORPORATION ANNOUNCES PEER-REVIEWED CLINICAL PUBLICATION COMPARING THE USE OF RENUVION TO A COMPETING TECHNOLOGY FOLLOWING LIPOSUCTION OR BODY CONTOURING PROCEDURES READ MORE
By Nick Johnson (Apyx) In 2024 Shareholder News, J-Plasma, RenuvionPosted August 8, 2024APYX MEDICAL CORPORATION REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS; UPDATES FULL YEAR 2024 FINANCIAL OUTLOOK READ MORE
